Parallel phase I study of ixabepilone plus lapatinib and ixabepilone plus lapatinib plus capecitabine in subjects with HER2 [human epidermal growth factor receptor 2] positive locally advanced or metastatic breast cancer.
Phase of Trial: Phase I
Latest Information Update: 11 Mar 2016
At a glance
- Drugs Ixabepilone (Primary) ; Capecitabine; Lapatinib
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 01 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Jun 2010 Planned end date changed from 1 Feb 2011 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.